A carregar...
Publicação
Biovantage - a company focused on the new frontier of drug development via organ-on-a-chip technology: competitive landscape & business Model
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 955.44 KB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
Within the "Building Companies Based on Science" field lab, this thesis focuses on creating
BioVantage, a startup leveraging state-of-the-art organ-on-chip (OoC) technology to transform
preclinical drug development. Anchored by a licensed neuromuscular junction-on-chip (NMJ OoC), BioVantage will initially specialize in neuromuscular diseases while exploring future
applications for heart- and liver-OoC. By integrating artificial intelligence in combination with
the OoC technology, our venture not only enhances the cost- and time-effectiveness and
accuracy of drug discovery, but also significantly reduces the reliance on animal testing. In this
report we detail a strategic business plan for BioVantage, positioning it as an ethical and
innovative partner in advancing preclinical drug research while redefining industry standards.
Descrição
Palavras-chave
Amyotrophic lateral sclerosis Animal testing Artificial Intelligence Contracted research organization Lambert-Eaton Myasthenic Syndrome Myasthenia gravis Neuromuscular diseases Organ-on-a-chip Science-based entrepreneurship